Nutra Pharma Receives Regulatory Approval to Market Nyloxin in India

Nutra Pharma Has Received Approval in India for Its Nyloxin Line of Pain Relievers

The Company Has Also Accepted Orders for Immediate Distribution from India-Based Importers to Support the Launch, Marketing and Sales of Nyloxin™ Throughout India

CORAL SPRINGS, Fla.--(BUSINESS WIRE)-- Nutra Pharma Corporation (OTCBB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received approval in India for its Nyloxin™ line of pain relievers. Following the approval, Nutra Pharma has accepted orders for the products through their distributor, Nutritional Alliance, for export to India-based importers.

“The India approval is our first regulatory authorization overseas and represents one of the more significant international market opportunities for Nyloxin,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India represents a potentially significant customer base for Nyloxin,” he added.

According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India’s population in need of opioids for pain relief had access to them.

Founded in 2000, Nutritional Alliance has grown into one of the premier sales brokerage firms in the United States specializing in products intended for food, drug and mass distribution as well as products intended for medical distribution. Currently, Nutritional Alliance works with many of the largest retailers and medical product distributors throughout North America, Europe and South America. Nutritional Alliance was named as Nutra Pharma's Global Sales Agent in October, 2010.

“We were honored that Nutra Pharma partnered with us on their distribution and growth of Nyloxin,” commented Jim Airaghi, Founder and President of Nutritional Alliance. “We have already been working diligently with domestic and international distributors. The registration in India represents the first step in our global marketing plan that we believe will make Nyloxin one of the most exciting healthcare products of 2011,” he added.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

Previously, Nutra Pharma announced agreements with distributors in Mexico, Colombia, Venezuela, Lebanon and Jordan. The drug registration process for both Cobroxin® and Nyloxin™ are currently being pursued in more than 20 countries.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit:

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Receiving regulatory approval for Nyloxin in India should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock, the Company’s future financial value or the Company’s future product sales. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


Nutra Pharma Corp.
Nina Goldstein, 877-895-5647
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  Florida  India

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Hospitals  Infectious Diseases  Pharmaceutical  Other Health  General Health